Floatz logo

Low Dose Lx2006

Cardiomyopathy, Secondary

Lexeo Therapeuticsgene_therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Cardiomyopathy, Secondary cohort.

Asset / SponsorPhaseRating
High Dose Lx2006
Lexeo Therapeutics
Phase 1/2CCC

Same molecule, other indications

Low Dose Lx2006 is also rated in:

Friedreich ataxiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →